Clinical trial

Pharmacokinetic Analysis of Bupivacaine in the Presence and Absence of Perineural Dexamethasone in Axillary Brachial Plexus Blockade for Distal Forearm and Hand Surgery

Name
OAIC 1249/22
Description
The investigators will conduct a prospective, randomized, double-blinded study using an axillary brachial plexus block in patients undergoing elective surgery of the distal forearm and hand to characterize and describe the pharmacokinetics of bupivacaine associated with perineural dexamethasone. The pharmacokinetic analysis will be performed by measuring bupivacaine plasma levels at different time intervals after the blockade (15, 30, 45, 60, and 90 minutes), allowing comparison between 2 different groups: Bupivacaine (B) and Bupivacaine-dexamethasone (BD). Thus, the hypothesis is that plasma levels of bupivacaine during the first 90 minutes after a blockade are lower in the presence of perineural dexamethasone, suggesting a decrease, at least initially, in systemic absorption from the injection site.
Trial arms
Trial start
2022-06-28
Estimated PCD
2023-04-17
Trial end
2023-04-24
Status
Completed
Phase
Early phase I
Treatment
Bupivacaine Hydrochloride
Patients will receive a total volume of 30 ml of bupivacaine 0.5% in an axillary block with a double puncture.
Arms:
Perineural Bupivacaine
Bupivacaine Hydrochloride with Dexamethasone
Patients will receive a total volume of 30 ml of bupivacaine 0.5% with Dexamethasone 4 mg in an axillary block with a double puncture.
Arms:
Perineural Bupivacaine plus Dexamethasone
Size
20
Primary endpoint
Maximum plasma concentration (Cmax) of bupivacaine
0 to 90 minutes after the ending time of local anesthetic injection
Eligibility criteria
Inclusion Criteria: * American Society of Anesthesiologists classification 1-2 * Real weight between 80 and 100 kg * Body mass index between 20 and 30 Exclusion Criteria: * Adults who are not capable of giving their own consent * Medical history or physical findings of pre-existing neuropathy * Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50) * Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100) * Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100) * Allergy to local anesthetics (LAs) * Pregnancy * Previous surgery in the axillary region of the surgical side
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'TRIPLE', 'maskingDescription': 'A research assistant (licensed anesthesiologist) will prepare the local anesthetic solutions and will add the study drug following the randomization order. The operator, patient and investigator assessing the block will be blinded to group allocation.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 20, 'type': 'ACTUAL'}}
Updated at
2023-10-17

1 organization

2 products

3 indications

Indication
Analgesic
Indication
Pain